Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Mar;63(3):451-8.
doi: 10.1161/HYPERTENSIONAHA.113.02026. Epub 2013 Dec 9.

Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort

Affiliations
Free PMC article
Comparative Study

Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort

David A Calhoun et al. Hypertension. .
Free PMC article

Abstract

Refractory hypertension is an extreme phenotype of antihypertensive treatment failure. Participants in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study, a large (n=30 239), population-based cohort were evaluated to determine the prevalence of refractory hypertension and associated cardiovascular risk factors and comorbidities. Refractory hypertension was defined as uncontrolled blood pressure (systolic/diastolic, ≥140/90 mm Hg) on ≥5 antihypertensive drug classes. Participants with resistant hypertension (systolic/diastolic, ≥140/90 mm Hg on ≥3 or <140/90 mm Hg on ≥4 antihypertensive classes) and all participants treated for hypertension served as comparator groups. Of 14 809 REGARDS participants receiving antihypertensive treatment, 78 (0.5%) had refractory hypertension. The prevalence of refractory hypertension was 3.6% among participants with resistant hypertension (n=2144) and 41.7% among participants on ≥5 antihypertensive drug classes. Among all participants with hypertension, black race, male sex, living in the stroke belt or buckle, higher body mass index, lower heart rate, reduced estimated glomerular filtration rate, albuminuria, diabetes mellitus, and history of stroke and coronary heart disease were associated with refractory hypertension. Compared with resistant hypertension, prevalence ratios for refractory hypertension were increased for blacks (3.00; 95% confidence interval, 1.68-5.37) and those with albuminuria (2.22; 95% confidence interval, 1.40-3.52) and diabetes mellitus (2.09; 95% confidence interval, 1.32-3.31). The median 10-year Framingham risk for coronary heart disease and stroke was higher among participants with refractory hypertension when compared with those with either comparator group. These data indicate that although resistant hypertension is relatively common among treated patients with hypertension, true antihypertensive treatment failure is rare.

Keywords: diabetes mellitus, type 2; hypertension; risk factors; therapeutics.

Conflict of interest statement

Conflicts of Interest/Disclosures: During the time of the study, Dr. Calhoun received salary support from Novartis Pharmaceuticals and was a consultant for Lilly Pharmaceuticals.

During the time of this study, Dr. Safford received salary support from Amgen, Inc. and diaDexus, and was a consultant for diaDexus. Dr. Muntner has received a research grant from Amgen, Inc.

Figures

Figure 1
Figure 1
Use of antihypertensive medication classes among study participants with refractory hypertension (n=78). ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; Beta: beta antagonist; Alpha: alpha antagonist; MRA: mineralocorticoid receptor antagonist; Central: central acting agent.

Comment in

Similar articles

See all similar articles

Cited by 41 articles

  • Clinical care & blood pressure control among hypertensive people living with human immune deficiency virus: Prospective cohort study.
    Melaku T, Chelkeba L, Mekonnen Z. Melaku T, et al. Ann Med Surg (Lond). 2020 May 5;54:114-124. doi: 10.1016/j.amsu.2020.04.017. eCollection 2020 Jun. Ann Med Surg (Lond). 2020. PMID: 32426130 Free PMC article.
  • Kang Le Xin Reduces Blood Pressure Through Inducing Endothelial-Dependent Vasodilation by Activating the AMPK-eNOS Pathway.
    Zhao Y, Zhu J, Liang H, Yang S, Zhang Y, Han W, Chen C, Cao N, Aruhan, Liang P, Du X, Huang J, Wang J, Zhang Y, Yang B. Zhao Y, et al. Front Pharmacol. 2020 Jan 22;10:1548. doi: 10.3389/fphar.2019.01548. eCollection 2019. Front Pharmacol. 2020. PMID: 32038237 Free PMC article.
  • Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.
    Magvanjav O, Cooper-Dehoff RM, McDonough CW, Gong Y, Hogan WR, Johnson JA. Magvanjav O, et al. Am J Hypertens. 2020 Apr 1;33(4):316-324. doi: 10.1093/ajh/hpz196. Am J Hypertens. 2020. PMID: 31853537
  • Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension.
    Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Siddiqui M, et al. Hypertension. 2020 Feb;75(2):510-515. doi: 10.1161/HYPERTENSIONAHA.119.14137. Epub 2019 Dec 9. Hypertension. 2020. PMID: 31813346
  • [Austrian Consensus on High Blood Pressure 2019].
    Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C, Brandt MC, Dichtl W, Ferrari J, Föger B, Henkel M, Hohenstein-Scheibenecker K, Horn S, Kautzky-Willer A, Kepplinger E, Knoflach M, Koppelstätter C, Mache C, Marschang P, Mayer G, Metzler B, Oberbauer R, Obermair F, Obermayer-Pietsch B, Perl S, Pilz S, Prischl FC, Podczeck-Schweighofer A, Rebhandl E, Rohla M, Roller-Wirnsberger R, Saely CH, Siostrzonek P, Slany J, Stoschitzky K, Waldegger S, Wenzel RR, Weiss T, Wirnsberger G, Winhofer-Stöckl Y, Zweiker D, Zweiker R, Watschinger B; Österreichische Gesellschaft für Hypertensiologie; Österreichische Atherosklerosegesellschaft; Österreichische Diabetes Gesellschaft; Österreichische Gesellschaft für Internistische Angiologie; Österreichische Gesellschaft für Nephrologie; Österreichische Kardiologische Gesellschaft; Österreichische Gesellschaft für Neurologie; Österreichische Schlaganfall-Gesellschaft; Österr. Gesellschaft für Allgemeinmedizin; Österr. Gesellschaft für Geriatrie; Österreichische Gesellschaft für Endokrinologie und Stoffwechsel; Österreichische Gesellschaft für Innere Medizin; Österreichische Gesellschaft für Kinder- und Jugendheilkunde. Weber T, et al. Wien Klin Wochenschr. 2019 Nov;131(Suppl 6):489-590. doi: 10.1007/s00508-019-01565-0. Wien Klin Wochenschr. 2019. PMID: 31792659 German.
See all "Cited by" articles

Publication types

Substances

Feedback